Roche weighs a $10B deal for partner Chugai

Roche ($RHHBY) is taking a hard look at partner Chugai Pharmaceutical, according to a report, considering whether to pay about $10 billion to buy the remaining shares of the company. As Bloomberg reports, Roche already holds a 62% stake in the Tokyo-headquartered drugmaker and may announce a full buyout as early as next week. More

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.